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Introduction
As cardiac dysfunction increases, the synthesis and release 
of cardiac natriuretic peptides gradually rises in concert with 
th other neurohormonal responses observed in heart fail-
ure.
1) Therefore, it has been proposed that increased B-type 
natriuretic peptide (BNP) and/or N-terminal pro-BNP (NT-
proBNP) be used as a marker for symptomatic ventricular 
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ABSTRACT
Background and Objectives: B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels may serve as a 
useful marker of cardiovascular risk for screening of the general population. We evaluated reference levels and distribution of 
NT-proBNP in the Korean general population based on a large cohort study. Subjects and Methods: We included 1,518 adult 
subjects (ages 40-69) of a community-based cohort from the Korea Rural Genomic Cohort (KRGC) Study. Thorough biochemi-
cal and clinical data were recorded for all subjects. Levels of NT-proBNP from all participants were determined. In order to 
determine normal reference levels, subjects with factors known to influence NT-proBNP levels were excluded. Results: The 
characteristics of the cohort are described below; subjects were 41.2% male, and the mean age was 54.8±8.4 years. The distri-
bution of risk factors for cardiovascular disease in the cohort included hypertension (25%), left ventricular hypertrophy by 
electrocardiography (ECG-LVH) (15%), hypercholestolemia (4.5%), smoking (32%), diabetes (10.9%), history of coronary 
heart disease (4.9%), history of heart failure (0.9%), symptoms of heart failure (6.1%), elevated serum creatinine (≥1.5, 3.7%), and 
severe obesity (body mass index >30 kg/m
2, 4.6%). The levels of NT-proBNP of all subjects are shown below; the mean was 
60.1±42.1, and the median was 36.5 pg/mL. In addition, the levels of NT-proBNP of normal subjects (which did not have any 
risk factors, n=224) are shown below; the mean was 40.8, and the median was 32.1 pg/mL. In normal subjects, the NT-
proBNP level was slightly higher in females (25.7±24.8 vs. 46.9±35.4, p<0.001). NT-proBNP level increased with age in both 
the normal population and the total population. There were no significant differences in NT-proBNP levels in subjects who 
smoked, or had diabetes mellitus, hypertension or ECG-LVH. However, in subjects with a history of congestive heart failure 
(CHF) (58.5±103.29 vs. 213.8±258.8, p<0.005), elevated serum creatinine levels (≥1.5 mg/dL, 146.2±98.2 vs. 54.3±38.1, p< 
0.001), or who were older (≥60, 48.4 vs. 84.2±139.5 pg/mL, p<0.05), the BNP level was higher. In addition, patients with more 
than 3 risk factors for CHF had higher BNP levels (risk 0: 40.8±34.0, 1-2: 57.4±93.2, ≥3: 85.0±152.9 pg/mL). NT-proBNP lev-
els were also related with age, sex, urine albumin, serum Cr, and high sensitivity C-reactive protein (p<0.05). Conclusion: We 
determined the reference value and distribution of NT-proBNP in the Korean adult general population. We also found that ad-
justments for the independent effects of age, sex and renal function appear necessary when determining cardiac risk based on 
proBNP levels. (Korean Circ J 2010;40:645-650) 
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dysfunction.
2-5) In addition, irrespective of the degree of left 
ventricular dysfunction, blood BNP or NT-proBNP levels 
have been shown to be elevated in patients with many cardi-
ac disorders, including previous myocardial infarction, cardio-
myopathy, valvular heart disease, hypertensive heart disease, 
and atrial fibrillation.
6-9) The Framingham study demonstrat-
ed that subjects with higher plasma BNP levels exhibited an 
increased incidence of congestive heart failure (CHF).
10) It is 
therefore possible that BNP or NT-proBNP levels may serve as 
a useful marker of cardiovascular risk in screening of the gen-
eral population.
11)12) However, recent reports have shown that 
in the general population, the plasma BNP or NT-proBNP le-
vel is affected by many extracardiac factors including age, 
obesity, and genetics.
13-15) However there are few studies on the 
normal reference levels and distribution of NT-proBNP in the 
Korean general population. 
Therefore, by using our large and well-characterized cohort 
sample, we sought to establish reference levels of NT-proBNP 
for healthy individualsand to identify the factors influencing 
NT-proBNP levels in the general Korean population.
Subjects and Methods
Study subjects
Subjects were selected from the Korean Genomic Rural Co-
hort, an ongoing epidemiologic study conducted on a repre-
sentative senior population (age >40 years) of Koreans. Of 
3,508 Korean adult subjects 1,437 were men {(mean age; 56.9± 
7.9) and 2,071 were women (mean age; 55.8±8.1)}. We includ-
ed 1,518 adult subjects from 3 of 5 total cohort areas for the 
NT-proBNP assay. Thorough biochemical and clinical data 
were recorded for all of the participants. Subjects each respond-
ed to a questionnaire on their medico-social history and life 
style characteristics. 
In addition, all subjects filled out a heart failure question-
naire about their medical history, symptoms, and drug his-
tory. Symptoms of heart failure were determined from ques-
tions on ankle swelling and dyspnea grade.
16) All subjects pro-
vided their informed consent, and the protocol was approved 
by the Ethics Committee of Yonsei University, Wonju College 
of Medicine, Wonju, Korea. 
Definitions of the normal population and the at-risk
population 
We defined “normal subjects” as follows: No history of coro-
nary heart disease (myocardial infarction and/or angina pec-
toris), stroke, CHF, diabetes mellitus (medical record or chemi-
cal examination), renal dysfunction (≥1.5 mg/dL); and no his-
tory of cardiovascular symptoms including dyspnea (>grade 
III), chronic lung disease, chest pain, edema, electrocardiogram 
(ECG) abnormality, or hypertension (hypertension: systolic 
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg, or having a antihypertensive medication history). We 
included age in evaluating factors that affect NT-proBNP level.
Laboratory measurements 
Blood samples were collected to analyze biochemical mark-
ers including plasma NT-proBNP, plasma creatinine, and rou-
tine chemistry. All blood samples were collected with the par-
ticipant in a sitting position and after at least 15 minutes of rest. 
Blood samples for analyses of the biochemical markers were 
immediately centrifuged at 4°C and plasma samples were stor-
ed in disposable tubes containing aprotinin (a kallikrein in-
hibitor) in a -80°C freezer. Plasma concentrations of NT-pro 
BNP were measured by a novel, highly sensitive and specific 
immunoassay, based on a sandwich format using unextracted 
EDTA plasma (Roche). The intra-assay and interassay coeffi-
cient of variation for serum in NT-proBNP assays ranged be-
tween 2.3% and 5.4%.
Statistical analysis
For continuous variables, results were expressed as mean 
±SD. Because the variability of NT-proBNP increased with 
its mean level, the natural log transformation was used in the 
regression analyses to satisfy modeling assumptions.
Two sample t-tests were performed to compare the mean or 
geometric mean values of variables in normal patients, to all 
other patients. Tests were also performed to compare the mean 
or geometric mean values of variables between men and wom-
en. Pearson’s correlation coefficient was used to establish the as-
sociation between serum NT-proBNP concentrations and 
clinical and laboratory parameters. Multivariate stepwise lo-
gistic regression analyses were performed to identify indepen-
dent predictors of serum NT-proBNP level. All analyses were 
done using the Windows-based SPSS statistical package (ver-
sion 10.0, Chicago, IL, USA), and p<0.05 were considered of 
significant.
Fig. 1. Prevalence of risk factors for congestive heart failure in co-
hort subjects. CHD: coronary heart disease, HF: heart failure, BMI: 
body mass index, DM: diabetes mellitus, LVH: left ventricular hy-
pertrophy, ECG: electrocardiogram, s-Cr: serum creatinine.
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Results
Characteristics of the study population
Of 1,518 subjects, 627 were male (41.3%), and the mean age 
was 54.8±8.4 years. Risk factors for CHF included hyperten-
sion (25%), left ventricular hypertrophy (LVH) by ECG (15%), 
hypercholestolemia (4.5%), smoking (32%), diabetes mellitus 
(DM) (10.9%), history of coronary heart disease (4.9%), his-
tory of CHF (0.9%) heart failure symptoms (6.1%), elevated 
serum Cr (≥1.5, 3.7%), and obesity {(body mass index (BMI) ≥ 
30, 4.6%} (Fig. 1). Of 1,518 subjects, the ‘normal’ population 
having no risk factors was 224 (14.8%, mean age 52.2±6.8), 
and the population of subjects with risk factors was 1,294 
(85.2%, mean age 55.7±9.3). 
The reference levels and distribution of N-terminal
pro-B-type natriuretic peptide 
Plasma NT-proBNP levels were found to range widely, with 
a distribution skewed lower, towards a normal distribution af-
ter log transformation (Fig. 2A). The mean level of NT-pro 
BNP for all subjects was was 60.1±42.1, the median level was 
36.5 pg/mL, and the range was 5-1,425 pg/mL (Fig. 2A). Addi-
tionally, the mean level of NT-proBNP for normal subjects was 
45.1±86.1, the median level was 31.5 pg/mL, and the range was 
5-297 pg/mL. In normal subjects, the level for 97.5% of was 130 
pg/mL (Fig. 2B). 
The correlation of N-terminal pro-B-type natriuretic
peptide levels with clinical factors
In the total population, NT-proBNP levels were not signifi-
cantly different between men and women (59.6±128.2 vs. 60.4 
±88.6, p>0.05). However in normal subjects the mean plasma 
NT-proBNP level was slightly higher in females (25.7±24.8 vs. 
46.9±35.4, p<0.001) (Fig. 3). The mean plasma NT-proBNP 
level increased with age in both groups. The mean plasma NT-
proBNP level broke down by age as follows in the total popula-
tion: for groups 40-49, 50-59, and 60-69, levels were 36.2±49.1, 
57.5±102.2 and 84.2±139.4 pg/mL, respectively (p<0.01). We 
Fig. 2. The distribution of NT-proBNP levels from cohort study. A: total population. B: normal population. NT-proBNP: N-terminal pro-B-type 
natriuretic peptide.
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evaluated the mean level of NT-proBNP according to presence 
of risk factors. There were no significant differences in subjects 
who smoked, or had DM, hypertension or left ventricular hy-
pertrophy by electrocardiography (ECG-LVH). However, NT-
proBNP levels were higher in patients who had a history of 
CHF (213.8±258.8 vs. 58.5±103.29, p<0.001) (Fig. 4B), a high 
Fig. 4. The effect of risk factors (A) and presence of CHF (B) on 
NT-pro BNP levels. Data represent mean±SE. *p<0.05, †p<0.005 
among different groups in the same population. CHF: congested heart 
failure, NT-proBNP: N-terminal pro-B-type natriuretic peptide, SE: 
standard error.
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Fig. 3. The effect of gender on NT-proBNP levels in the normal pop-
ulation and total population. Data represent mean±SE. *p<0.05, 
†p<0.005 among different groups in the same population. NT-proB-
NP: N-terminal pro-B-type natriuretic peptide. SE: standard error.
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serum creatinine level (≥1.5 mg/dL, 146.2±98.2 54.3±38.1, 
p<0.001) or who were older (≥60, 48.4 vs. 84.2±139.5 pg/mL, 
p<0.005). In subjects with severe obesity (BMI ≥30 kg/m
2, 
62.4±119.3 vs. 52.1±61.9), NT-proBNP level was lower but the 
difference was not significant (p=0.068). Fig. 4A shows the co-
rrelation between subject’s plasma NT-proBNP level and the 
number of their cardiovascular disease risk factors. These fac-
tors include advanced age (≥60 years), hypertension, history of 
coronary heart disease, mildly elevated serum creatinine level, 
major ECG abnormalities, smoking history, diabetes melli-
tus, and obesity. Patients with more than 3 factors had higher 
NT-proBNP levels (risk 0: 40.8±34.0, 1-2: 57.4±93.2, ≥3: 85.0 
±152.9 pg/mL, p<0.005) (Fig. 4A).
The relationship between N-terminal pro-B-type 
natriuretic peptide and clinical factors
Subjects with plasma NT-proBNP levels ≥97.5 percentile 
of the gender-age reference level were designated as the high 
BNP group (n=704). Logistic regression analysis was perform-
ed to examine independent clinical factors contributing to 
high NT-proBNP levels. NT-proBNP levels were related to age, 
BMI, urine albumin, serum Cr, and high sensitivity C-reac-
tive protein (hs-CRP) (p<0.05). Among these variables, age and 
high serum creatinine levels were most strongly related to 
high NT-proBNP levels (Table 1). 
Discussion
In this study, the main findings can be summarized as fol-
lows. First, we evaluated the reference levels of plasma NT-
proBNP in the Korean adult general population using a large 
cohort study, and we determined a cut-off value for abnormal 
NT-proBNP level. Second, we demonstrated NT-proBNP lev-
els depend on physiological conditions including gender, age, 
and BMI, in addition to pathological risk factors. Finally, we 
determined that old age, gender, and elevated serum creatinine 
or hs-CRP levels were significant independent variables asso-
ciated with high plasma NT-proBNP levels.
N-terminal pro-B-type natriuretic peptide levels 
depend on subject’s physiological condition
Generally, the covariates affecting NT-proBNP concentra-
tion were age, sex and BMI.
13-15) Some reports have shown that 
healthy women typically have NT-proBNP concentrations 1.4 
times higher than men.
16)17) According to our data, in healthy 
women the NT-proBNP level was 1.6 times higher than men, 
however in the total population the NT-proBNP level was not 
different. This may be partially because this group of men has 
more subjects with elevated creatinine level than the general 
population. Age is another powerful predictor of increased 
NT-proBNP levels in normal subjects.
18-20) In our study, sub-
jects age 50-59 have a mean NT-proBNP value 1.6 times high-
er than those age 60-69, and 2.3 times higher than those age 
40 to 49. These differences appear to be related to physiolog-
ical or pathological conditions (such as renal function, LVH, 
hypertension and CHF). When pathological disease was ex-
cluded, slightly higher NT-proBNP values were noted in sub-
jects age 50-59 years compared to those age 40-49. Wang et al.
14) 
reported an inverse relationship between BNP and BMI in a 
non-obese, healthy subgroup of the Framingham Heart Study 
offspring cohort, and BMI was an independent negative cor-
relate of BNP in heart failure patients. However, according to 
our data, while BMI may negatively impact NT-proBNP, the 
effect is not as impressive or significant as that of age and gen-
der. Ethnicity was also an important factor when considering 
reference values. It was previously reported that in patients 
with acute coronary syndromes or acute dyspnea, slightly hi-
gher NT-proBNP values were obtained in whites than in bla-
cks.
18-20) While though there is no report comparing to East 
Asian to western people, it is possible there are differences be-
cause of ethnicity itself or because of demographic and physi-
ological variables. Establishing normal values is essential to 
the interpretation of results for an individual patient. Not all 
of the subjects who were considered “normal” in our cohort 
study were completely healthy. While we evaluated detailed 
patient history, some of the patients might have asymptom-
atic cardiac dysfunction or other noncardiac conditions. Be-
cause complete cardiac evaluation was not performed, it is th-
eoretically possible that a small minority of the subjects had 
altered NT-proBNP levels due to their conditions.
21)
N-terminal pro-B-type natriuretic peptide levels 
depending on pathological conditions and 
their relationship to clinical factors
Smoking, DM, hypertension, and ECG-LVH have been re-
ported to affect NT-proBNP levels.
22-25) However in our data 
they appear to have no affect. Because we did not evaluate pre-
Table 1. Regression analysis of various clinical parameters on high 
NT-proBNP level in total subjects
Beta value t value Significance
Sex 0.098 3.123 0.002
CVD Hx -0.039 -1.523 0.128
BMI -0.026 -1.010 0.313
SBP 0.037 1.444 0.149
s-Cr (≥1.5) 0.218 7.143 0.000
hs-CRP 0.055 2.156 0.031
Urine albumin 0.015 0.577 0.564
Age 0.169 6.281 0.000
DM 0.019 0.712 0.477
model significance; p=0.000. NT-proBNP: N-terminal pro-B-type 
natriuretic peptide, BMI: body mass index, hs-CRP: high sensitivity 
C-reactive protein, DM:diabetes mellitus, CVD Hx: cardiovascular 
disease history, SBP: systolic hypertension, s-Cr: serum creatinineKyung-Hoon Lee, et al.   649
cise left ventricular function and hypertrophy by echocar-
diography, we do not know if there was left ventricular hyper-
trophy or dysfunction in subjects with DM, hypertension, or 
ECG-LVH. We would have needed to perform morphologi-
cal analysis of the left ventricle. Usually, both BNP and the ami-
no-terminal fragment of its pro-hormone (NT-proBNP) are 
elevated in patients with renal dysfunction and end-stage renal 
disease.
26)27) However the relationship between renal function, 
circulating NT-proBNP have not been fully elucidated. We 
found no independent relationship between serum creatinine 
and NT-proBNP in normal patients. However in the total pop-
ulation, subjects with high serum creatinine level had high 
NT-proBNP levels, and high serum creatinine level was the 
most strong correlated factor with high NT-proBNP levels.
Some have reported that renal impact is minor if the de-
gree of dysfunction is small.
26) However our data showed in-
terdependence between renal impairment and elevated NT-
proBNP.
27) This may be because NT-proBNP does not have a 
clearance receptor, so its clearance may be influenced by renal 
function.
28)
Clinical implications
When considering the application of cutoff points, it is al-
ways necessary to acknowledge the population to which they 
apply;
29) thus, cutoff points derived for a healthy population 
might not necessarily apply to an acutely ill population or a 
hospitalized population. Plasma NT-proBNP levels may be 
elevated in subjects with precursors of CHF, and thus may 
serve as a useful predictor for the new onset of CHF. They mi-
ght also be useful for high risk recognition in a screening set-
ting in the general population.
10-11)30) 
To the best of our knowledge, this is the first study to pro-
vide reference plasma NT-proBNP values in a Korean com-
munity-based population. We suggest that this reference val-
ue will serve as a useful reference for NT-proBNP for screening 
of general population. As Framingham and others have report-
ed, BNP or NT-proBNP is a well known risk factor for CHF 
or cardiovascular death.
10)31) It is important to identify subjects 
at high risk for CHF with asymptomatic heart disease who 
will be prone to develop overt CHF. The present study dem-
onstrates high plasma BNP levels may serve as a marker for 
subjects with an increased risk of CHF. 
Taken together, adjustments for the independent effects of 
age and sex appear necessary in considering the reference val-
ue for normal plasma NT-proBNP. In addition, we have iden-
tified many other confounding variables involved in the inter-
pretation of a given plasma NT-proBNP concentration, and of 
these impaired renal function seems to be the most important.
Limitations
Our study has several limitations. The first is selection bias. 
It is possible there may be differences between this regional co-
hort and data from a real demographic background in Korea. 
In our study, we excluded subjects greater than age 70 because 
of the original cohort design. Second, although we obtained 
the reference level after careful history evaluation and exami-
nation for hypertension, ECG abnormality, previous cardio-
vascular disease, cardiovascular medications, and cardiac 
symptoms, we did not performed echocardiography in all par-
ticipations. We are performing an ongoing study involving ec-
hocardiography in same cohort. Finally, analytical problems 
were possible in our cohort study. Although NT-pro BNP was 
more stable than BNP,
32) there are always possible effects from 
sample storageand collection. These issues must be considered 
when examining our reference levels.  
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